Captix Biomedical Pty Ltd
Captixbio is a pioneering Australian company developing innovative medical technologies to optimise the therapeutic impact of cell therapies. Captixbio’s IMITATM device is an immuno-protective cell encapsulation technology intended to transform the current cell therapy paradigm for treatment of Type 1 diabetes. Captixbio is dedicated to transforming the lives of millions of people globally, who currently live with Type 1 diabetes.
The choice you make above will help our platform display content that is best suited to you
Welcome to the new Wholesale Investor platform. Please use your existing log in details to access the site. Alternatively feel free to use the "Login with LinkedIn" or "Sign in with Google" buttons.
Enter your email to reset your password.